Alendronate and Atrial Fibrillation

Publisher Website
Google Scholar
Abstract
In this issue of the Journal, Black et al.1 report on a significant increase in the risk of serious atrial-fibrillation adverse events (defined as events resulting in hospitalization or disability or judged to be life-threatening) associated with once-yearly infusions of intravenous zoledronic acid for the treatment of osteoporosis in postmenopausal women. However, there was no increased risk of all adverse events of atrial fibrillation with such infusions.